BlueGem Capital Partners LLP has acquired an 80% stake in Big Fernand
BlueGem Capital Partners LLP has acquired an 80% stake in Big Fernand from its founders.
BlueGem Capital Partners LLP is a London-based mid-market private equity firm established in 2007, with assets under management of over US$500 million raised from a global investor base. The firm seeks to invest between US$25–75 million of equity in medium sized business in selected countries in Western Europe with an enterprise value between US$50–300 million. BlueGem's focus and sector expertise is in branded consumer facing businesses and strategic distribution platforms (wholesale and retail).
Big Fernand was founded in September 2011 by Steve Burggraf, Alexandre Auriac and Guillaume Pagliano. Its first restaurant opened in January 2012 in Paris. In 2013, two more restaurants opened in Paris and Lyon, and in 2014, five in the Paris region, Nantes and Lille. The company started its international expansion to Hong Kong and London in 2015. Big Fernand specializes in burgers made from premium meat. The firm focuses on quick and good service and on French branding and marketing.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Related deals
ELSA Group has sold SoFine Foods to The New Originals Company
The New Originals Company has acquired SoFine Foods from the ELSA Group.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more